AVITA Therapeutics Stock News

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ:RCEL) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 7, 2025, AVITA released its second quar...

AVITA Medical, Inc. (NASDAQ:RCEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants James Corbett - CEO, President & Executive Director Presentation Unknown Analyst Okay. Thank you, everybody, for joining us.

LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) investors concerning the Company's possible violations of the federal securities laws.

BENSALEM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) investors concerning the Company's possible violations of federal securities laws.

LOS ANGELES, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) on behalf of investors concerning the Company's possible violations of federal securities laws.

Investors can contact the law firm at no cost to learn more about recovering their losses

On August 8, 2025, Avita shares fell 21% to $4.25 after revealing unpaid Recell claims caused a demand drop due to CMS pricing and adjudication delays.